A practical reference on post-marketing surveillance: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-17. Anything still debated is marked as such rather than presented as settled.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular mass | About 1024.2 g/mol | Monoisotopic value for the free base |
| Appearance | White to off-white lyophilized powder | Visual inspection is not an identity test |
| Solubility | Soluble in water and polar organic solvents | Dissolution depends on salt form and pH |
| Typical storage | -20 °C, dry, protected from light | Powder is more stable than prepared solutions |
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
. If there is just a single detector, then the analyzer can sweep across the mass spectrum one slit at a time. With multiple detectors, the speed of analysis increases. A pure magnetic sector analyzer can achieve resolution ~10,000. With an added electrostatic focusing field before or after the magnetic sector, the analyzer can achieve resolution ~100,000. Particularly unstable ions may disintegrate while passing through the analyzer. If it undergoes the reaction Mz+ → M'z+ + (other parts) when entering the analyzer, it would undergo a circular motion of radius
NASA engineers had not yet worked out the idiosyncrasies of orbital mechanics involved in rendezvous, which are counter-intuitive. Simply thrusting the spacecraft toward the target changed its orbital altitude and velocity relative to the target. When McDivitt tried this, he found himself moving away and downward, as the retrograde thrust lowered his orbit, increasing his speed. The stage was dumping its residual propellant, causing it to move around in various directions relative to the Gemini. There were only two running lights on the stage, which made it hard at times for McDivitt to determine its orientation. McDivitt concluded that a rendezvous target should have at least three lights. There was no radar on board Gemini 4 to give a precise range to the target, so the astronauts had to rely on their visual depth perception to estimate the range, and this differed for the two men. Initially McDivitt estimated the distance at 400–500 feet (120–150 m), while White believed that it was closer ("a little over 200 feet (61 m)"). At the worst point, McDivitt estimated it was about a half mile (800 meters) away, while White's estimate was three-quarters of a mile (1200 meters). McDivitt estimated that he was able to get as close as 200 feet (61 m), but now White's estimate was between 850 and 1,000 feet (260 and 300 m). After expending almost half his thruster fuel, McDivitt finally gave up, in order to concentrate on the more important EVA objective.
If there is no hypoglycemia at the time of the symptoms, this condition is called idiopathic postprandial syndrome. It might be an "adrenergic postprandial syndrome" — blood glucose levels are normal, but the symptoms are caused through autonomic adrenergic counterregulation. Often, this syndrome is associated with emotional distress and anxious behaviour of the patient. This is often seen in dysautonomic disorders as well. Dietary recommendations for reactive hypoglycemia can help to relieve symptoms of postprandial syndrome.
Sources: en.wikipedia.org
== Regulation == Regulation of the CGRP gene is in part controlled by the expression of the mitogen-activated protein kinase (MAPK) signaling pathway and cytokines like TNFα and iNOS. 5HT1 receptor agonists like sumatriptan increase intracellular calcium, which causes decreases in CGRP promoter activity. CGRP receptors are found in myelinated A-fiber axons which is required for ligand specificity and function of the receptor. The CGRP receptor has three subunits: receptor activity-modifying protein 1 (RAMP1), calcitonin-like receptor (CLR) and receptor component protein (RCP). The complex central receptor is the G protein-coupled receptor calcitonin receptor-like receptor (CALCRL) which is necessary for CGRP and adrenomedullin (AM receptors). For function CGRP, CALCRL must coincide with RAMP1 where the ligand-binding domain of CGRP is located. It also includes two cytoplasmic proteins that associate with the CALCRL-RAMP1 to form signal transduction. CALCRL contains the Gα subunit, which activates adenylyl cyclase and cAMP-dependent signaling pathways. Receptor-mediated transduction elevates in intracellular cAMP activate protein kinase A, which results in the phosphorylation of multiple targets, including potassium- sensitive ATP channels (KATP channels), extracellular signal-related kinases and transcription factors such as cAMP-responsive element-binding protein (CREB). In smooth muscle of the neurovascular region, the elevation of cAMP upon CGRP activation results in vasodilation of the blood vessel. Chronic exposure to CGRP causes degradation of lysosomes.
In real-world settings, a review of more than 40,000 patient records found that while methadone and buprenorphine reduced risk of fatal overdose, naltrexone administration showed no greater effect on overdose or subsequent emergency care than counseling alone. Despite these findings, naltrexone's manufacturer and some health authorities have promoted the medicine as superior to methadone and buprenorphine since it is not an opioid and does not induce dependence. The manufacturer has also marketed directly to law enforcement and criminal justice officials, spending millions of dollars on lobbying and providing thousands of free doses to jails and prisons. The technique has been successful, with the criminal justice system in 43 states now incorporating long-acting naltrexone. Many do this through Vivitrol courts that offer only this option, leading some to characterize this as "an offer that cannot be refused." The company's marketing techniques have led to a Congressional investigation, and warning from the FDA about failure to adequately state risks of fatal overdose to patients receiving the medicine. In May 2017, United States Secretary of Health and Human Services Tom Price praised [Vivitrol] as the future of opioid addiction treatment after visiting the company's plant in Ohio. His remarks set off sharp criticism with almost 700 experts in the field of substance use submitting a letter to Price cautioning him about Vivitrol's "marketing tactics" and warning him that his comments "ignore widely accepted science".
== Medical use == Delafloxacin is indicated to treat adults with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria or adults with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria. Susceptible bacteria for ABSSSI are:
== External links == A Detailed Glycolysis Animation provided by IUBMB (Adobe Flash Required) The Glycolytic enzymes in Glycolysis at RCSB PDB Glycolytic cycle with animations at wdv.com Metabolism, Cellular Respiration and Photosynthesis – The Virtual Library of Biochemistry, Molecular Biology and Cell Biology The chemical logic behind glycolysis at ufp.pt Expasy biochemical pathways poster Archived 2010-06-20 at the Wayback Machine at ExPASy MedicalMnemonics.com: 317 5468 metpath: Interactive representation of glycolysis Archived 2015-04-02 at the Wayback Machine
Sources: en.wikipedia.org
Later, Klink and crew left the Antarctic Circle, visiting Margarida Bay in the Bellingshausen Sea (in the extreme south of the Antarctic Peninsula). From there, the ship stopped in South Georgia before returning to Brazil.
21CFR50.3: Code of Federal Regulations, Title 21--Food and Drugs, Chapter I--Food and Drug Administration, Department of Health and Human Services, Part 50--Protection of Human Subjects, Subpart A--General Provisions, Sec. 50.3 Definitions 21CFR312.3: Code of Federal Regulations, Title 21--Food and Drugs, Chapter I--Food and Drug Administration, Department of Health and Human Services, Part 312--Investigational New Drug Application, Subpart A--General Provisions, Sec. 312.3 Definitions and Interpretations, archived from the original on June 26, 2003 ICH E6: Guidance for Industry - E6 Good Clinical Practice: Consolidated Guidance (PDF), U.S. Department of Health and Human Services, Food and Drug Administration, April 1996, archived from the original (PDF) on July 9, 2009 ICH E9: Guidance for Industry - E9 Statistical Principles for Clinical Trials (PDF), U.S. Department of Health and Human Services, Food and Drug Administration, September 1998, archived from the original (PDF) on July 10, 2009 NCI: Dictionary of Cancer Terms, National Cancer Institute, archived from the original on 2008-10-25, retrieved 2008-10-05 NLM: Glossary of Clinical Trials Terms, U.S. National Library of Medicine, archived from the original on 2011-09-02, retrieved 2008-10-05
=== Visual effects === The companies that were in charge of creating the visual effects for the season were Pixomondo, Rocket Science VFX, MPC Episodic, Soho VFX, Ingenuity Studios, Rising Sun Pictures, Studio 8, and Outpost VFX. Stephan Fleet was in charge of being the VFX supervisor once again after working for the previous seasons. Fleet revealed that the season would have bigger visual effects than the previous seasons but will keep the characters and story that was created by the creators of the series. Laz Alonso revealed that the season used over three times the amount of blood more than the previous season: "I'll put it to you this way. I was talking to the head makeup artist and she's in charge of ordering the blood — that's one of her many jobs. She told me that all of Season 2 ... When you talk about bulk, I don't think they used over a gallon of blood in Season 2, believe it or not. Season 3, we're already at three and a half gallons of blood. So that should give you a little indication of where it's going." Rocket Science VFX was in charge of the creation of series fire explosions, Soldier Boy's powers, and the body and head explosions, by taking a 3D environment work since the creation of the effects would be heavier. To achieve Soldier Boy's powers, the crew looked for real radioactive blast to have them combined with FX fire and make blast simulations. Rising Sun Pictures worked to get the effects of the destruction provoqued through the series and captured over 100 shots during the season.
Sources: en.wikipedia.org
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.
Mass spectrometry establishes molecular mass, and reversed-phase chromatography reports purity. Peptide mapping or amino acid analysis supports sequence-level confirmation. No single technique covers all failure modes, so laboratories combine results.
Common entries include appearance, purity by chromatographic area, measured mass, and sometimes residual solvents or counter-ion content. Methods and instrument conditions are not always described. The document reflects the supplier's own testing unless an independent laboratory is named.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.